Valuation: Alvotech

Market Cap 1.22B 1.07B 980M 914M 1.73B 116B 1.76B 11.8B 4.57B 57.01B 4.58B 4.48B 196B P/E 2026 *
9.02x
P/E 2027 * 8.26x
Enterprise Value 2.32B 2.03B 1.86B 1.74B 3.29B 221B 3.35B 22.41B 8.69B 108B 8.71B 8.52B 373B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 2.95x
Free-Float
36.65%
Yield 2026 *
-
Yield 2027 * -
1 day+0.84%
Current month-61.51%
Current year-61.51%
5 years 3.55
Extreme 3.55
10.44
10 years 3.55
Extreme 3.55
11.62
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap.
20/09/20OthersCompany 218,750 3.8889%
15/09/20OtherCompany 0 0%
15/09/20OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%-61.76% - - 1.22B
+1.36%+6.73%+2.48%+7.78% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+5.46%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.26%+0.35%+13.41%+18.82% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +1.54%+4.67%+71.53%+104.01% 26.92B
Weighted average by Cap. +1.72%+5.25%+89.03%+131.73%

Financials

2026 *2027 *
Net sales 663M 580M 532M 496M 941M 63.16B 957M 6.41B 2.48B 30.98B 2.49B 2.44B 107B 792M 692M 636M 593M 1.12B 75.43B 1.14B 7.65B 2.97B 37B 2.98B 2.91B 127B
Net income 165M 144M 132M 123M 234M 15.7B 238M 1.59B 618M 7.7B 619M 606M 26.54B 134M 117M 108M 100M 190M 12.76B 193M 1.3B 502M 6.26B 503M 492M 21.57B
Net Debt 1.1B 960M 882M 822M 1.56B 105B 1.59B 10.62B 4.11B 51.32B 4.13B 4.04B 177B 1.12B 978M 898M 838M 1.59B 107B 1.61B 10.81B 4.19B 52.27B 4.2B 4.11B 180B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
02/07/26 US$3.610 +0.84% 479,403
01/07/26 US$3.580 -2.98% 883,002
30/06/26 US$3.690 -0.81% 853,940
29/06/26 US$3.720 +1.09% 690,357
26/06/26 US$3.680 +5.75% 991,866
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.610USD
Average target price
14.60USD
Spread / Average Target
+304.43%

Quarterly revenue - Rate of surprise